Αρχική World News Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment... World News Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC Από Ogkologos - 25 Ιουνίου, 2025 685 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer 21 Μαΐου, 2024 Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... 22 Μαρτίου, 2023 Pine Trees or COVID? 2 Σεπτεμβρίου, 2020 First immunotherapy approved for cervical cancer in England and Scotland 16 Μαΐου, 2023 Φόρτωση περισσοτέρων HOT NEWS Breast Cancer Patient Does Head-Shaving Photo Shoot in Hopes of Inspiring... EMA Recommends Granting a Marketing Authorisation for Acalabrutinib Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’